Drugs / SOLCITINIB
SOLCITINIB
also known as
GSK2586184 · GLPG0778 · G-154578 · GLPG-0788 · GSK-2586184A · GSK2586184 new formulation · GSK2586184 new formulation without poloxamer · GSK2586184 standard formulation
Small molecule targets JAK1 via inhibition
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02000453 | Dec 2013 → Aug 2014 | ulcerative colitis | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT01953835 | Oct 2013 → Mar 2014 | systemic lupus erythematosus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01336244 | Apr → Aug 2011 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT01278108 | Dec 2010 → Feb 2011 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01782664 | Mar 2013 → Mar 2014 | psoriasis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01777256 | Mar 2013 → Mar 2014 | systemic lupus erythematosus | GlaxoSmithKline | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01687309 Comparator | Apr → Jul 2012 | systemic lupus erythematosus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOLCITINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301606 ↗ |
| Known as | G-154578 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301606 ↗ |
| Known as | GLPG-0788 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301606 ↗ |
| Known as | GLPG0778 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01278108 ↗ |
| Known as | GSK-2586184A | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301606 ↗ |
| Known as | GSK2586184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01687309 ↗ |
| Known as | GSK2586184 new formulation | “GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet.” NCT01953835 ↗ |
| Known as | GSK2586184 new formulation without poloxamer | “GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet.” NCT01953835 ↗ |
| Known as | GSK2586184 standard formulation | “GSK2586184 standard formulation is a white film coated round biconvex 200 mg oral tablet.” NCT01953835 ↗ |
| Action | Inhibit | “the selective JAK1 inhibitor GSK2586184” PMID 27055521 ↗ Jul 2016 |
| Modality | Small molecule | — CHEMBL3301606 ↗ |
| Route | Oral | “Single Ascending Oral Doses” NCT01278108 ↗ |
| Target | JAK1 | “the selective JAK1 inhibitor GSK2586184” PMID 27055521 ↗ Jul 2016 |